Tonix Reports Q2 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals announced that TONMYA net sales increased 197% quarter-over-quarter to approximately $11 million. The company also reported approximately $176.2 million in cash and cash equivalents and provided operational updates on its clinical pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day